Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels

Dec. 29, 2022 1:41 PM ETBiogen Inc. (BIIB) StockAVXL, LLY, BIIB31 Comments
The Political Economist
675 Followers

Summary

  • A new as-yet-unreported death among those taking Biogen's Lecanemab in an extended post-Phase 3 study has emerged.
  • Biogen's Lecanemab has a PDUFA date of January 6, 2023; the FDA will announce its preliminary (or final) approval or rejection.
  • Six days later, Anavex Life Sciences will likely announce the final results of its Phase 2b/3 trial for its Alzheimer's drug.
  • By the 13th, the future of possible Alzheimer's treatments will likely be much clearer.

MRI scan of human brain and skull

haydenbird

People can die from the side effects of drugs. It happens every day. Read the warning labels of your pharmaceutical products.

It's not shocking that Biogen/Eisai's (NASDAQ:BIIB) new Alzheimer's medication causes some terrible side effects for a

This article was written by

The Political Economist
675 Followers
I am interested in writing what others have not written. For instance, I plan on detailing how the Biden solar import duty (tax) policy is the greatest blockade in the growth of clean energy on our planet. My particular areas of interest include clean energy, Alzheimer's drugs, and yieldco companies. My articles on Alzheimer's drugs have attracted a great deal of attention among those interested in the disease. I have written on a number of clean energy companies, including Canadian Solar, JinkoSolar, Clean Energy Fuels, Westport Fuel Systems, Kandi Technologies, and so forth. Sometimes I do not answer questions to my articles because I am too busy or too stressed, especially when dealing with trolls or people who purposefully try to deceive. I am not talking about shorts in general. Most shorts are okay people. I live in the United States, and my parents are survivors of two wars. They eventually immigrated here, married and gave birth to two children.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of AVXL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I do not have a short position in BIIB, LLY, or AVXL, nor will I initiate a short position in BIIB, LLY or AVXL.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About BIIB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BIIB

Related Stocks

SymbolLast Price% Chg
BIIB
--
Compare

Trending Analysis

Trending News